Cerenome, Inc. (CNSY)
0.6301
-0.07
(-10.29%)
USD |
NASDAQ |
Nov 20, 16:00
0.6301
0.00 (0.00%)
After-Hours: 20:00
Cerenome EPS Diluted (Quarterly) : -1.144 for Sept. 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -1.144 |
| June 30, 2026 | -1.305 |
| March 31, 2026 | -1.045 |
| December 31, 2025 | -1.03 |
| September 30, 2025 | -1.029 |
| June 30, 2025 | -0.1628 |
| March 31, 2025 | -29.86 |
| December 31, 2024 | -16.55 |
| September 30, 2024 | -0.3658 |
| June 30, 2024 | -0.2737 |
| March 31, 2024 | -0.7546 |
| December 31, 2023 | -0.8424 |
| September 30, 2023 | -0.998 |
| June 30, 2023 | -0.5906 |
| March 31, 2023 | -2.071 |
| December 31, 2022 | -2.526 |
| September 30, 2022 | -2.853 |
| June 30, 2022 | -3.560 |
| March 31, 2022 | -2.871 |
| December 31, 2021 | -4.018 |
| September 30, 2021 | -4.211 |
| June 30, 2021 | -3.718 |
| March 31, 2021 | -4.935 |
| December 31, 2020 | -10.95 |
| September 30, 2020 | -5.888 |
| Date | Value |
|---|---|
| June 30, 2020 | -6.806 |
| March 31, 2020 | -4.202 |
| December 31, 2019 | 4.198 |
| September 30, 2019 | -0.5082 |
| June 30, 2019 | -96.30 |
| March 31, 2019 | -167248.5 |
| December 31, 2018 | -5971.31 |
| September 30, 2018 | -10362.19 |
| June 30, 2018 | -11125.69 |
| March 31, 2018 | -525.00 |
| December 31, 2017 | -1500.00 |
| September 30, 2017 | -1050.00 |
| June 30, 2017 | -1425.00 |
| March 31, 2017 | -61875.00 |
| December 31, 2016 | -1800.00 |
| September 30, 2016 | -1950.00 |
| June 30, 2016 | -3225.00 |
| March 31, 2016 | -691871.6 |
| December 31, 2015 | -2250.00 |
| September 30, 2015 | 1125.00 |
| June 30, 2015 | 3375.00 |
| March 31, 2015 | -23625.00 |
| December 31, 2014 | -9000.00 |
| September 30, 2014 | -13500.00 |
| June 30, 2014 | -16875.00 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 15.72 |
| Ernexa Therapeutics, Inc. | -1.885 |
| ACADIA Pharmaceuticals, Inc. | 0.305 |
| Anika Therapeutics, Inc. | -0.0232 |
| Savara, Inc. | -0.1691 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -8.657M |
| Revenue (Quarterly) | 0.722M |
| Total Expenses (Quarterly) | 9.379M |
| Enterprise Value | 4.075M |
| Gross Profit Margin (Quarterly) | -48.34% |
| Profit Margin (Quarterly) | -1.20K% |
| Earnings Yield | -718.1% |
| Normalized Earnings Yield | -725.27 |